TY - JOUR
T1 - Dietary Therapy and Nutrition Management of Eosinophilic Esophagitis
T2 - A Work Group Report of the American Academy of Allergy, Asthma, and Immunology
AU - Eosinophilic Gastrointestinal Disorders Committee of the American Academy of Allergy, Asthma and Immunology
AU - Groetch, Marion
AU - Venter, Carina
AU - Skypala, Isabel
AU - Vlieg-Boerstra, Berber
AU - Grimshaw, Kate
AU - Durban, Raquel
AU - Cassin, Alison
AU - Henry, Michelle
AU - Kliewer, Kara
AU - Kabbash, Lynda
AU - Atkins, Dan
AU - Nowak-Węgrzyn, Anna
AU - Holbreich, Mark
AU - Chehade, Mirna
N1 - Funding Information:
Conflicts of interest: M. Groetch has received lecture fees from Nutricia North America. C. Venter has received consultancy fees from Danone, Nestle, and Mean Johnson. I. Skypala is on the European Academy of Allergy and Clinical Immunology (EAACI) Executive Committee; has received travel support from EAACI; has received consultancy fees from ALK-Abelló; has received lecture fees from Belgium allergy dietitians group, the Food Allergy Specialist Group of the British Dietetic Association, and Nutricia; has received travel support from the American Academy of Asthma, Allergy, and Immunology and the British Society of Allergy and Clinical Immunology. B. Vlieg-Boerstra has received research support from Nutricia Research; and has received lecture fees from Mead Johnson and Nutricia Advanced Medical Nutrition. K. Grimshaw has received consultancy fees from Reacta Biotech; has received lecture fees from Danone and Abbott; and has received travel support from Abbott. R. Durban and A. Cassin have received personal fees from Nutricia North America. D. Atkins is on the American Partnership for Eosinophilic Disorders medical advisory board (unpaid); is on the DBV Technologies data monitoring safety board for the Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy (MILES) study; has received lecture fees from Regeneron Inc.; and has received travel support from Monsanto. A. Nowak-Węgrzyn is the Merck DMC Chair; has received consultancy fees from Aimmune and Nestle; is employed by Icahn School of Medicine; has received research support from DBV, Food Allergy Research & Education (FARE), National Institute of Health (NIH), and ThermoFisher; has received lecture fees and payment for manuscript preparation from Nestle; receives royalties from UpToDate; has received payment for developing educational presentations from Annenberg Center; and is Chair of the Medial Advisory Board, International FPIES Organization. M. Chehade is a Medical Advisory Panel member of American Partnership for Eosinophilic Disorders (APFED) (nonpaid position) and a Medical Advisory Board member of the International FPIES Association (nonpaid position); has received consultancy fees from Acelion, Receptos, and Shire; and has received research support from Nutricia and Regeneron. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2016 American Academy of Allergy, Asthma & Immunology
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Eosinophilic esophagitis (EoE) is a chronic/immune-antigen-mediated disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Dietary elimination therapy has been shown to be an effective, drug-free prescription for the treatment of EoE. A range of different dietary elimination therapies have been used. Regardless of the elimination diet chosen, dietary therapy requires in-depth nutrition assessment and management. Elimination diets are not without risk and may impact nutritional status, eating pleasure, and overall quality of life. With adequate guidance, dietary therapy can be effective and nutritionally balanced, and the adverse impact on lifestyle can be minimized. This work group report addresses the potential challenges of implementing an elimination diet for the management of EoE and provides instructions and tools for physicians, dietitians, and other allied health professionals to help guide them in planning elimination diets for both children and adults.
AB - Eosinophilic esophagitis (EoE) is a chronic/immune-antigen-mediated disease characterized clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-predominant inflammation. Dietary elimination therapy has been shown to be an effective, drug-free prescription for the treatment of EoE. A range of different dietary elimination therapies have been used. Regardless of the elimination diet chosen, dietary therapy requires in-depth nutrition assessment and management. Elimination diets are not without risk and may impact nutritional status, eating pleasure, and overall quality of life. With adequate guidance, dietary therapy can be effective and nutritionally balanced, and the adverse impact on lifestyle can be minimized. This work group report addresses the potential challenges of implementing an elimination diet for the management of EoE and provides instructions and tools for physicians, dietitians, and other allied health professionals to help guide them in planning elimination diets for both children and adults.
KW - Dietary therapy
KW - Dietitian
KW - Elimination diet
KW - Eosinophilic esophagitis
KW - Growth
KW - Nutrition
UR - http://www.scopus.com/inward/record.url?scp=85021658994&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2016.12.026
DO - 10.1016/j.jaip.2016.12.026
M3 - Article
C2 - 28283156
AN - SCOPUS:85021658994
SN - 2213-2198
VL - 5
SP - 312-324.e29
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 2
ER -